Top Stories
The neuropsychiatry biotech builds on last year's $140 million launch as Phase II studies of its lead depression drug DT-101 continue.
Avere's deal with Hansoh Pharmaceutical, potentially worth over $2 billion, is backed by a $320-million private placement.
After partner GSK successfully gained FDA approval of the antibiotic Utebzi (tebipenem pivoxil) in June, Spero is pivoting to immunology and inflammation via a licensing agreement with Innovent Biologics.
The oral EGFR inhibitor is approved in China and the US for previously-treated EGFR exon 20 insertion-positive non–small-cell lung cancer, and is pursuing a first-line indication.
The PPAR agonist met its primary endpoint in the Phase IIIb ELSPIRE trial involving patients with primary biliary cholangitis (PBC) and alkaline phosphatase levels 1 to 1.67 times the upper limit of normal.
Conference News
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc...
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026Preclinical data for sutacimig in Factor VII d...
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –– Updated data expected to support darlif...
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)New analys...
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteersRepresents one of the first quantitative measures of tr...
